Sarepta Addresses Questions about Status of Clinical Trial Programs

June 9, 2022

On June 9, 2022, Sarepta provided a community update on their actively recruiting clinical trial programs for Duchenne muscular dystrophy.

For the most up to date information on clinical trials, please refer to

1. What Sarepta clinical trials are currently recruiting?
Below is a brief review of Sarepta clinical trials currently recruiting in our Duchenne muscular dystrophy pipeline. The information below is not comprehensive but intended to give an overview. Those interested in pursuing a clinical trial should discuss it with their physician. More information can be found on using the NCT (national clinical trial) numbers indicated below.

2. Are you planning a gene therapy trial for an expanded population?
We are planning a trial for older ambulatory and non-ambulatory individuals and will share details of this trial and others as we draw nearer to start dates.

3. Why is there a study evaluating eteplirsen when it has been approved in the United States?
As part of an FDA postmarketing study requirement, MIS51ON is evaluating a higher dose of eteplirsen and comparing it to the approved 30 mg/kg dose. There is no placebo group in this study, rather, participants will receive a higher dose of eteplirsen or the approved30 mg/kg dose.

4. Once enrolled in a Sarepta clinical trial, what support can I expect?
We are committed to providing a positive experience for the individuals living with Duchenne and their families who participate in our trials. We regularly incorporate community feedback into the design of our trials in order to reduce study participant burden and to make trials more inclusive and accessible to all. In general, reasonable travel, accommodation and meals while traveling to and from the site are financially covered by Sarepta, and Sarepta provides support staff to help with travel co-ordination. Please note, country relocation is not supported. We recommend discussing this with your physician and reaching out to study sites if you have questions about participation.

5. Will the COVID 19 vaccine affect my/my child’s potential participation in a gene therapy trial?
For more information about COVID 19 vaccine and clinical trials, please refer to our Community Bulletin: COVID-19 Vaccination and Gene Therapy.

6. How do I learn more about the clinical trials listed above?
Each clinical trial has a NCT # associated with it. You may go to and search in “other terms” for the NCT #. There, you will find more information about the trial and contact information for sites that are currently recruiting. You may also reach out to for any specific questions about Sarepta clinical trials.

7. Where can I find additional information about clinical trials in general?
Please visit for additional information about clinical trial considerations. Additionally, feel free to reach out to for other questions.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open